Abstract
Objectives To determine whether elevated blood pressure influences risk for respiratory infection.
Design Prospective, population-based epidemiological and Mendelian randomisation studies.
Setting UK Biobank.
Participants 377,143 self-identified British descent (54% women; median age 58 years) participants in the UK Biobank.
Main outcome measures First incident pneumonia over an average of 8 follow-up years.
Results 107,310 (30%) participants had hypertension at UK Biobank enrolment, and 9,969 (3%) developed a pneumonia during follow-up. Prevalent hypertension at baseline was significantly associated with increased risk for incident respiratory disease including pneumonia (hazard ratio 1.36 (95% confidence interval 1.29 to 1.43), P<0.001), acute respiratory distress syndrome or respiratory failure (1.43 (1.29 to 1.59), P<0.001), and chronic lower respiratory disease (1.30 (1.25 to 1.36), P<0.001), independent of age, age2, sex, smoking status, BMI, prevalent diabetes mellitus, prevalent coronary artery disease, and principal components of ancestry. Mendelian randomisation analyses indicated that genetic predisposition to a 5 mmHg increase in blood pressure was associated with increased risk of incident pneumonia for SBP (1.08, (1.04 to 1.13), P<0.001) and DBP (1.11 (1.03 to 1.20), P=0.005). Additionally, consistent with epidemiologic associations, increase in blood pressure genetic risk was significantly associated with reduced forced expiratory volume in the first second, forced vital capacity, and the ratio of the two (P<0.001 for all).
Conclusions These results strongly suggest that elevated blood pressure independently increases risk for pneumonia and reduces pulmonary function. Maintaining adequate blood pressure control, in addition to other measures, may reduce risk for pneumonia. Whether the present findings are generalizable to novel coronavirus disease 2019 (COVID-19) require further study.
Section 1: What is already known on this topic
Hypertension has been associated with pneumonia in small observational studies.
Based on early epidemiologic analyses, hypertension is described as a risk factor for SARS-CoV-2 infection and associated novel coronavirus disease 2019 (COVID-19).
The influence of hypertension on pneumonia risk is difficult to assess in traditional observational studies.
Section 2: What this study adds
Our pre-COVID-19 analyses are consistent with a causal relationship between increased blood pressure and increased risk for incident respiratory infections, as well as between increased blood pressure and reduced pulmonary function.
These results support hypertension as a pneumonia risk factor; efforts to optimize blood pressure may reduce risk for pneumonia.
Competing Interest Statement
P.N. reports investigator-initiated grants from Amgen, Apple, and Boston Scientific, and consulting income from Apple and Blackstone Life Sciences. The remaining authors have nothing to disclose.
Funding Statement
S.M.Z. is supported by the National Institutes of Health’s NHLBI under award number 1F30HL149180-01 and the National Institutes of Health’s Medical Scientist Training Program at the Yale School of Medicine. M.C.H. is supported by the National Institutes of Health (T32HL094301-07). P.N. is supported by a Hassenfeld Scholar Award from the Massachusetts General Hospital, and grants from the National Heart, Lung, and Blood Institute (R01HL1427, R01HL148565, and R01HL148050) and Fondation Leducq (TNE-18CVD04). Disclosures: P.N. reports investigator-initiated grants from Amgen, Apple, and Boston Scientific,
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All of the individual-level data used in the manuscript are available by application through the UK Biobank (https://www.ukbiobank.ac.uk).
